Targeting S1PR1/STAT3 loop abrogates desmoplasia and chemosensitizes pancreatic cancer to gemcitabine

Rationale: Pancreatic cancer is associated with poor prognosis with a 5-year survival rate of less than 6%. Approximately 90% of pancreatic cancer patients harbor somatic mutations in the KRAS gene. Multiple lines of evidence suggest a persistent activation of STAT3 in KRAS-driven oncogenesis contri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Theranostics
Glavni autori: Lankadasari, Manendra Babu, Aparna, Jayasekharan S., Mohammed, Sabira, James, Shirley, Aoki, Kazunori, Binu, Valsalakumari S., Nair, Sindhu, Harikumar, Kuzhuvelil B.
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2018
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6071521/
https://ncbi.nlm.nih.gov/pubmed/30083262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.25308
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items